Search

Search Constraints

You searched for: Author/Creator Barclay, Stephen T.

Search Results

1. Comparing Predicted Probability of Hepatocellular Carcinoma in Patients With Cirrhosis With the General Population: An Opportunity to Improve Risk Communication?. (24th September 2022)

2. Declining incidence of hepatitis C related hepatocellular carcinoma in the era of interferon‐free therapies: A population‐based cohort study. (5th January 2022)

3. Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis. Issue 4 (13th December 2019)

4. Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: Implications for reinfection. (1st September 2015)

5. Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs. (1st August 2016)

6. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials. Issue 11 (8th September 2021)

7. Real‐world impact following initiation of interferon‐free hepatitis C regimens on liver‐related outcomes and all‐cause mortality among patients with compensated cirrhosis. Issue 3 (26th November 2019)

8. Real‐world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype. Issue 10 (1st July 2020)

9. The prevalence and impact of thrombocytopenia, anaemia and leucopenia on sustained virological response in patients receiving hepatitis C therapy: evidence from a large 'real world' cohort. Issue 4 (April 2016)

10. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause‐specific outcomes. Issue 2 (25th March 2015)